Amneal Pharmaceuticals Inc. Class A

3.32-0.0800-2.35%Vol 786.44K1Y Perf -34.87%
Jun 28th, 2022 16:00 DELAYED
BID3.30 ASK3.39
Open3.38 Previous Close3.40
Pre-Market- After-Market3.30
 - -  -0.02 -0.60%
Target Price
7.33 
Analyst Rating
Moderate Buy 2.50
Potential %
120.78 
Finscreener Ranking
★★★     48.48
Insiders Trans % 3/6/12 mo.
-/-/67 
Value Ranking
★★     46.03
Insiders Value % 3/6/12 mo.
-/-/99 
Growth Ranking
★★+     49.27
Insiders Shares Cnt. % 3/6/12 mo.
-/-/99 
Income Ranking
 —    -
Price Range Ratio 52W %
13.59 
Earnings Rating
Sell
Market Cap500.68M 
Earnings Date
8th Aug 2022
Alpha-0.02 Standard Deviation0.16
Beta1.17 

Today's Price Range

3.313.53

52W Range

2.905.99

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
11.11%
1 Month
-1.73%
3 Months
-17.27%
6 Months
-32.27%
1 Year
-34.87%
3 Years
-52.58%
5 Years
-79.01%
10 Years
-84.18%

TickerPriceChg.Chg.%
AMRX3.32-0.0800-2.35
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 20220.100.100.00
Q04 20210.170.16-5.88
Q03 20210.190.190.00
Q02 20210.180.2327.78
Q01 20210.170.1911.76
Q04 20200.120.11-8.33
Q03 20200.120.138.33
Q02 20200.100.100.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.17-10.53Negative
9/2022 QR0.220.00-
12/2022 FY0.74-1.33Negative
12/2023 FY0.87-1.14Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report0.17
Estimates Count4
EPS Growth Next 5 Years %25.00
Volume Overview
Volume786.44K
Shares Outstanding150.81K
Shares Float102.19M
Trades Count3.68K
Dollar Volume2.70M
Avg. Volume682.86K
Avg. Weekly Volume628.16K
Avg. Monthly Volume682.24K
Avg. Quarterly Volume738.17K

Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 3.4 per share at the end of the most recent trading day (a 6.25% change compared to the prior day closing price) with a volume of 425.34K shares and market capitalization of 500.68M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5500 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.

The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is -34.87%, while year-to-date (YTD) performance is -29.02%. AMRX stock has a five-year performance of -79.01%. Its 52-week range is between 2.9 and 5.99, which gives AMRX stock a 52-week price range ratio of 13.59%

Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of 160.00, a price-to-book (PB) ratio of 1.23, a price-to-sale (PS) ratio of 0.24, a price to cashflow ratio of 2.30, a PEG ratio of 2.32, a ROA of 0.05%, a ROC of 2.56% and a ROE of 0.51%. The company’s profit margin is -0.07%, its EBITDA margin is 18.00%, and its revenue ttm is $2.10 Billion , which makes it $13.91 revenue per share.

Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Moderate Buy (2.5), with a target price of $7.33, which is +120.78% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amneal Pharmaceuticals Inc. Class A has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.14, ATR14 : 0.21, CCI20 : 17.54, Chaikin Money Flow : 0.09, MACD : -0.09, Money Flow Index : 50.64, ROC : 1.80, RSI : 51.85, STOCH (14,3) : 86.93, STOCH RSI : 1.00, UO : 48.79, Williams %R : -13.07), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Anastasios G. Konidaris (Option Excercise at a value of $0), Andrew S. Boyer (Option Excercise at a value of $0), Chintu Patel (Buy at a value of $1 251 000), Chirag Patel (Buy at a value of $1 251 000), Emily Peterson Alva (Option Excercise at a value of $0), Gautam Patel (Buy at a value of $421 000), Gautam Patel (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jeffrey P. George (Option Excercise at a value of $0), John J. Kiely (Option Excercise at a value of $0), Joseph Todisco (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Nikita Shah (Sold 4 000 shares of value $15 800 ), Paul M. Meister (Option Excercise at a value of $0), Shlomo Yanai (Option Excercise at a value of $0), Ted C. Nark (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
2 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (20.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Hold
2.60

Amneal Pharmaceuticals Inc. Class A

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.

CEO: Chintu Patel / Chirag Patel

Telephone: +1 908 947-3120

Address: 400 Crossing Boulevard, Bridgewater 08807, NJ, US

Number of employees: 5 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

61%39%

Bearish Bullish

64%36%

News

Stocktwits